TOP - September 2022 Vol 15, No 5

Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research annual meeting. Read More ›

This section provides a brief overview of new indications for cancer drugs approved by the FDA between June 22, 2022, and August 11, 2022. Read More ›